TABLE 3.
Characteristics of patients with hGISA infection
| Age (yr)/sexa | Date of LT (day/mo/yr) | Liver disease | MRSA nasal carriage before LT | Previous antibiotic treatmentb | Time of onset after LT (days) | Site of infectionc | PFGE pattern | Treatment (duration [days])d | Clinical outcome |
|---|---|---|---|---|---|---|---|---|---|
| 60/M | 03/06/98 | Alcoholic cirrhosis | No | TAZ | 15 | LRTI | 15 | VAN (19) | Improved |
| 48/M | 08/06/98 | Hepatitis B and D viruses | No | AMX/CLAV | 25 | Wound | 15 | Surgery | Improved |
| 54/M | 20/10/98 | Alcoholic cirrhosis | Yes | None | 10 | Blood, peritonitis | 16 | VAN (18) | Improved |
| 49/F | 28/12/98 | Polykystosis | No | IMI, CIP | 21 | LRTI | 15 | TEI + CTX (9) | Improved |
| TEI (6) | Failure | ||||||||
| 52/M | 02/02/99 | Alcoholic cirrhosis | No | CTX, OFLO | 6 | KT, blood, LRTI, abdomen | 17 | VAN (21) + CPO (8) | Improved |
| 46/M | 06/06/99 | Fulminant hepatitis | No | OXA, OFLO, CAZ, TAZ | 60 | LRTI, wound | 15 | VAN (15) + CTX and surgery | Improved |
| 50/M | 31/04/01 | Hepatitis C virus | Yes | CIP, VAN, TAZ | 2 | LRTI | 15 | VAN (12) | Improved |
| 56/M | 16/07/01 | Alcoholic cirrhosis | No | FEP, AMIK | 14 | LRTI | 15 | VAN + FEP (14) | Improved |
| 59/M | 02/09/01 | Alcoholic cirrhosis | No | AMX/CLAV | 12 | Abdomen | 15 | VAN (36) and surgery | Improved |
| 58/M | 07/11/01 | Budd-Chiari syndrome | No | TAZ, CIP, TEI | 12 | Blood, LRTI, abdomen | 12 | VAN + TAZ (9) + AMIK and surgery | Death |
a
M, male; F, female.
b
Antibiotics received in the 2 months preceding MRSA infection. Abbreviations: AMIK, amikacin; AMX/CLAV, amoxicillin-clavulanate; CAZ, ceftazidime; CIP, ciprofloxacin; CTX, cefotaxime; FEP, cefepime; IMI, imipenem; OFLO, ofloxacin; OXA, oxacillin; TAZ, piperacillin-tazobactam; TEI, teicoplanin; VAN, vancomycin.
c
LRTI, lower respiratory tract infection; KT, catheter.
d
CPO, cefpirome. The other antibiotic abbreviations are as defined in footnote b.